Estrogen Receptor Antagonist class drugs

2 results

  • Faslodex

    (Fulvestrant)
    AstraZeneca Pharmaceuticals LP
    Usage: FASLODEX is indicated for treating HR-positive, HER2-negative advanced breast cancer in postmenopausal women, either as monotherapy for untreated or progressing disease, or in combination with ribociclib, palbociclib, or abemaciclib following disease progression on prior endocrine therapy.

  • Orserdu

    (Elacestrant)
    Stemline Therapeutics, Inc.
    Usage: ORSERDU is indicated for treating postmenopausal women and adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one line of endocrine therapy.